CYCLACEL PHARMACEUTICALS INC's ticker is CYCC and the CUSIP is 23254L405. A total of 19 filers reported holding CYCLACEL PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $498,000 | -41.4% | 1,292,448 | +1.8% | 0.00% | -100.0% |
| Q4 2019 | $850,000 | +83.2% | 1,269,326 | +8.4% | 0.00% | – |
| Q3 2019 | $464,000 | -22.1% | 1,170,962 | +6.2% | 0.00% | -100.0% |
| Q2 2019 | $596,000 | +5.5% | 1,102,400 | +82.5% | 0.00% | 0.0% |
| Q1 2019 | $565,000 | +344.9% | 604,200 | +186.8% | 0.00% | – |
| Q4 2018 | $127,000 | -31.4% | 210,700 | +56.3% | 0.00% | – |
| Q3 2018 | $185,000 | +23.3% | 134,800 | +26.8% | 0.00% | – |
| Q2 2018 | $150,000 | +650.0% | 106,300 | +613.4% | 0.00% | – |
| Q1 2018 | $20,000 | -89.1% | 14,900 | -69.5% | 0.00% | – |
| Q2 2017 | $184,000 | -65.0% | 48,913 | -65.8% | 0.00% | -100.0% |
| Q1 2017 | $526,000 | -44.8% | 142,913 | -20.7% | 0.00% | -50.0% |
| Q4 2016 | $953,000 | -3.1% | 180,213 | +9.9% | 0.00% | 0.0% |
| Q3 2016 | $983,000 | +338.8% | 163,913 | +267.4% | 0.00% | – |
| Q2 2016 | $224,000 | – | 44,613 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 25,000 | $36,000 | 0.01% |
| Virtu Financial LLC | 29,033 | $41,000 | 0.00% |
| BREWIN DOLPHIN LTD | 5,586 | $7,932 | 0.00% |
| SIGNET FINANCIAL MANAGEMENT, LLC | 23 | $0 | 0.00% |
| UBS Group AG | 10,380 | $14,000 | 0.00% |
| D'Orazio & Associates, Inc. | 100 | $0 | 0.00% |
| DIMENSIONAL FUND ADVISORS LP | 12,240 | $17,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 83 | $0 | 0.00% |
| NORTHERN TRUST CORP | 13,399 | $19,000 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 21,692 | $30,000 | 0.00% |